M5717

Merck KGaA

Legend
Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management

  • Potential for prophylaxis
MoA

  • P. falciparum EF2 inhibitor novel mechanism of action
Key features

  • Comparable activity across all stages of the malaria parasite lifecycle 

  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for >8 days is 500mg 

  • Excellent transmission-blocking activity in a Standard Membrane Feeding Assay
Status
  • First-in-human study started in September 2017; volunteer infection study ongoing
Next milestone

  • Complete Phase I studies and move into patients with combination product
Previously
  • Names DDD107498; DDD498, MMV121; Discovery collaboration with the University of Dundee Drug Discovery Unit
MMV Project Director
  • Dr Jörg Möhrle